immunotherapy
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
New studies provide evidence that there may be fungi within tumors and could also help to diagnose certain types of cancer or predicting their course.
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Researchers have found that a specific microbial metabolite may boost the efficacy of anticancer therapy in people with TNBC. The findings could inform the development of improved treatments for TNBC.
Akkermansia can be used as a biomarker to identify who is likely to respond to treatment with immune checkpoint inhibitors. A new study published in Nature Medicine claims
A study published in Nature Medicine claims that the manipulation of the gut microbiota could be a new strategy to treat toxicity to combined immunotherapy.
Some gut microbial metabolites boost the efficacy of antitumor drugs by regulating the body’s immune response and could be used as a part of cancer therapy.
A new study published in Science claims that some gut microbes produce a metabolite that boosts the effect of a class of cancer drugs.
Researchers have created a catalog of the bacteria associated with all the cancer types. The findings could help to enhance the actions of anticancer drugs.
